Current Report Filing (8-k)
December 18 2015 - 4:31PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
______________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): December
17, 2015
SKYSTAR BIO-PHARMACEUTICAL COMPANY
(Exact Name of Registrant as Specified in
Its Charter)
Nevada
(State or Other Jurisdiction of Incorporation)
| 001-34394 |
33-0901534 |
| (Commission File Number) |
(IRS Employer Identification No.) |
| |
|
4/F Building B Chuangye Square,
No. 48 Keji Road, Gaoxin District, Xi’an
Shaanxi Province, P.R. China |
n/a |
| (Address of Principal Executive Offices) |
(Zip Code) |
(8629) 8819-3188
(Registrant’s Telephone Number, Including
Area Code)
n/a
(Former Name or Former Address, if Changed
Since Last Report)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see
General Instruction A.2. below):
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Item 3.01 | Notice of Delisting
or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing |
On December 17, 2015,
Skystar Bio-Pharmaceutical Company (the “Company”) received a notification from The Nasdaq Stock Market (“Nasdaq”)
informing the Company that a Nasdaq hearing panel had decided to delist the Company’s shares from Nasdaq and that the Company’s
shares would be suspended from trading on Nasdaq at the open of business on December 21, 2015.
The Company previously
disclosed a notification from Nasdaq informing the Company that is was subject to delisting because it failed to comply with Nasdaq’s
filing requirements set forth in Listing Rule 5250(c)(1) because it failed to file its Form 10-K for the fiscal year ended December
31, 2014, and Forms 10-Q for the periods ended March 31, and June 30, 2015. The failure to file the Quarterly Report constitutes
an additional basis for delisting. The Company also previously disclosed that Nasdaq had notified the Company of two additional,
and separate, bases for delisting under Listing Rule 5250(b)(1) (failure to disclose material non-public information) and Listing
Rule 5101 (public interest concerns).
On December 18, 2015,
the Company issued a press release relating to the foregoing event, a copy of which is attached hereto as Exhibit 99.1 and is incorporated
herein by reference.
| Item 9.01 | Financial Statements
and Exhibits. |
| 99.1 | Press release dated December
18, 2015. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: December 18, 2015
| |
SKYSTAR BIO-PHARMACEUTICAL COMPANY |
| |
|
| |
By: |
/s/ Bing Mei |
| |
Name: Bing Mei |
| |
Title: Chief Financial Officer |
Exhibit 99.1
SKYSTAR BIO-PHARMACEUTICAL COMPANY ANNOUNCES DELISTING FROM NASDAQ
Xi’an,
China, December 18, 2015 – Skystar Bio-Pharmaceutical Company (NASDAQ: SKBI), a China-based
manufacturer and distributor of veterinary medicine, vaccines, micro-organisms and feed additives, announced that on December 17,
2015, Skystar Bio-Pharmaceutical Company (the “Company”) received notification from The Nasdaq Stock Market (“Nasdaq”)
informing the Company that a Nasdaq hearing panel had decided to delist the Company’s shares from Nasdaq and that the Company’s
shares would be suspended from trading on Nasdaq at the open of business on December 21, 2015.
The
Company previously disclosed a notification from Nasdaq informing the Company that it was subject to delisting because it failed
to comply with Nasdaq’s filing requirements set forth in Listing Rule 5250(c)(1), because it failed to file its Form 10-K
for the fiscal year ended December 31, 2014, and Forms 10-Q for the periods ended March 31, and June 30, 2015. The failure to file
the Quarterly Report constitutes an additional basis for delisting. The Company also previously disclosed that Nasdaq had notified
the Company of two additional, and separate, bases for delisting under Listing Rule 5250(b)(1) (failure to disclose material non-public
information) and Listing Rule 5101 (public interest concerns).
The
Company will continue to work towards completing its filing requirements for the respective periods and other reports with the
Securities and Exchange Commission pursuant to the Exchange Act of 1934, as amended, and other federal securities laws.
The
Company expects to commence trading on the over-the-counter market on December 21, 2015.
About Skystar Bio-Pharmaceutical Company
Skystar is a China-based developer, manufacturer
and distributor of veterinary healthcare and medical care products. Skystar has four product lines: veterinary medicines, probiotics,
vaccines and feed additives formulated and packaged in house across several modern manufacturing and distributions facilities.
Skystar's distribution network includes almost 3,000 distribution agents of which 360 are franchised stores with exclusivity agreements
covering 29 provinces throughout China. For additional information, please visit http://www.skystarbio-pharmaceutical.com.
Safe Harbor Statements
When used in this release, the words "intends,"
"believes," "anticipated" and "expects" and similar expressions are intended to identify forward-looking
statements. Forward-looking statements include, without limitation, the Company’s ability to complete its IgG kit effort
as well as other related efforts at the Huxian facilities, the Company’s ability to timely, effectively and accurately assess
the efficacy and commercial potential of any technologies that may results from such R&D efforts, the Company’s ability
to timely and effectively commercialize any such technologies. The Company undertakes no obligation to publicly release the result
of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof
or to reflect the occurrence of unanticipated events.
Contact:
Skystar Bio-Pharmaceutical Company
Scott Cramer
Director - Corporate Development & U.S. Representative
(407) 645-4433